Peter J Goadsby

Dec 29, 2023 | healio.com | Peter J Goadsby |Nancy Hemphill |Bob Herpen

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Treatment with 100 mg of ubrogepant in the prodromal phase prevented development of headaches as soon as 24 hours post-dose compared with placebo, according to study co-author Peter J. Goadsby, MD, PhD, FRS.

Nov 15, 2023 | thelancet.com | David W Dodick |Peter J Goadsby

Summary Ubrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that is approved for acute treatment of migraine. The prodrome is the earliest phase of a migraine attack and is characterised by non-aura symptoms that precede headache onset. The aim of this trial was to evaluate the efficacy, safety, and tolerability of ubrogepant 100 mg compared with placebo for the acute treatment of migraine when administered during the prodrome.

Jul 18, 2023 | thelancet.com | Roberta Messina |Maria A Rocca |Peter J Goadsby

Cookie Preference CenterWe use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.

Apr 26, 2023 | neurologylive.com | Peter J Goadsby

WATCH TIME: 5 minutes Atogepant (Quilipta; AbbVie), an oral calcitonin gene-related peptide receptor antagonist, was originally approved in September 2021, based on the results of its full clinical development program, namely, the ADVANCE study (NCT02848326).1 Years later, in April 2023, the FDA expanded the indication for the treatment to include the prevention of chronic migraine in adults, adding to its existing indication for episodic migraine.2 At the 2023 American Academy of Neurology...